Ying-Chun Shen

List of Publications by Year
in descending order

41 papers	1,618 citations	331670 21 h-index	315739 38 g-index
43 all docs	43 docs citations	43 times ranked	2559 citing authors

#	Article	IF	Citations
1	Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study. , 2022, 10, e003697.		28
2	Dendritic cell immunoreceptor drives atopic dermatitis by modulating oxidized CaMKII-involved mast cell activation. JCI Insight, 2022, , .	5.0	11
3	Immune checkpoint inhibitors for hepatocellular carcinoma â€“ A game changer in treatment landscape. Journal of the Formosan Medical Association, 2022, 121, 1371-1383.	1.7	3
4	Effects of prophylactic high and low doses of corticosteroid on the efficacy of immune checkpoint blockade in murine hepatocellular carcinoma models.. Journal of Clinical Oncology, 2022, 40, e14596-e14596.	1.6	1
5	Abstract LB040: Targeting CD38 and PD-1 with isatuximab (Isa) plus cemiplimab (Cemi) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label, multicenter study. , 2021, , .		2
6	Evolution of systemic treatment for advanced hepatocellular carcinoma. Kaohsiung Journal of Medical Sciences, 2021, 37, 643-653.	1.9	11
7	An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 809-822.	3.7	17
8	Limited Predictive or Prognostic Role of Tumor-Infiltrating Tissue-Resident Memory CD8 T Cells in Patients with Hepatocellular Carcinoma Receiving Immunotherapy. Cancers, 2021, 13, 5142.	3.7	2
9	MCC950 Ameliorates Acute Liver Injury Through Modulating Macrophage Polarization and Myeloid-Derived Suppressor Cells Function. Frontiers in Medicine, 2021, 8, 752223.	2.6	6
10	Epithelial Aryl Hydrocarbon Receptor Protects From Mucus Production by Inhibiting ROS-Triggered NLRP3 Inflammasome in Asthma. Frontiers in Immunology, 2021, 12, 767508.	4.8	14
11	Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 489-497.	3.7	38
12	A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy. Oncologist, 2020, 25, e1280-e1285.	3.7	14
13	Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 480-490.	7.7	57
14	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2019, 13, 615-621.	3.0	5
15	Expression of human leukocyte antigen-a and b2-microglobulin in prostate cancer.. Journal of Clinical Oncology, 2019, 37, e16550-e16550.	1.6	1
16	Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model. Prostate Cancer and Prostatic Diseases, 2018, 21, 113-125.	3.9	46
17	Using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to predict efficacy of axitinib for treatment of advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2017, 35, e15656-e15656.	1.6	1
18	Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives. Journal of Hepatocellular Carcinoma, 2014, 1, 85.	3.7	17

#	Article	IF	Citations
19	Phase II Multicentered Study of Low-Dose Everolimus plus Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin as First-Line Treatment for Patients with Advanced Gastric Cancer. Oncology, 2014, 87, 104-113.	1.9	28
20	Clinical Trials in Hepatocellular Carcinoma: An Update. Liver Cancer, 2013, 2, 345-364.	7.7	58
21	A Critical Evaluation of the Preventive Effect of Antiviral Therapy on the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C or B: A Novel Approach by Using Meta-Regression. Oncology, 2012, 82, 275-289.	1.9	35
22	Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression. Gastric Cancer, 2012, 15, 265-280.	5.3	17
23	Authorâ€™s reply: Vitamin A and gastric cancer risk. Gastric Cancer, 2012, 15, 344-344.	5.3	16
24	Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. Journal of Hepatology, 2011, 55, 858-865.	3.7	114
25	Targeting Fibroblast Growth Factor Receptor Signaling in Hepatocellular Carcinoma. Oncology, 2011, 81, 372-380.	1.9	46
26	High Circulating Endothelial Progenitor Levels Associated with Poor Survival of Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib Combined with Metronomic Chemotherapy. Oncology, 2011, 81, 98-103.	1.9	19
27	Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. Journal of Gastroenterology, 2010, 45, 794-807.	5.1	61
28	Early alphaâ€fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer, 2010, 116, 4590-4596.	4.1	154
29	Induction of DNA Damage-Inducible Gene GADD45Î² Contributes to Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Cells. Cancer Research, 2010, 70, 9309-9318.	0.9	76
30	Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach. Journal of Hepatology, 2010, 52, 889-894.	3.7	125
31	Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B. Life Sciences, 2010, 86, 199-206.	4.3	33
32	Geographic difference in survival outcome for advanced hepatocellular carcinoma: Implications on future clinical trial design. Contemporary Clinical Trials, 2010, 31, 55-61.	1.8	46
33	Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. Journal of Hepatology, 2010, 53, 126-131.	3.7	124
34	Molecular Subtypes of Breast Cancer Emerging in Young Women in Taiwan: Evidence for More Than Just Westernization as a Reason for the Disease in Asia. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1807-1814.	2.5	103
35	Nuclear Overexpression of Mitotic Regulatory Proteins in Biliary Tract Cancer: Correlation with Clinicopathologic Features and Patient Survival. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 417-423.	2.5	24
36	Induction of Bim Expression Contributes to the Antitumor Synergy Between Sorafenib and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor CI-1040 in Hepatocellular Carcinoma. Clinical Cancer Research, 2009, 15, 5820-5828.	7.0	35

#	ARTICLE	IF	CITATIONS
37	Sorafenib for the treatment of hepatocellular carcinoma across geographic regions. Expert Review of Clinical Pharmacology, 2009, 2, 129-136.	3.1	11
38	Difference in the Incidence Trend of Nasopharyngeal and Oropharyngeal Carcinomas in Taiwan: Implication from Age-Period-Cohort Analysis. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 856-861.	2.5	65
39	Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung. Anti-Cancer Drugs, 2005, 16, 739-742.	1.4	2
40	Significant Difference in the Trends of Female Breast Cancer Incidence Between Taiwanese and Caucasian Americans: Implications from Age-Period-Cohort Analysis. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1986-1990.	2.5	130
41	Gastric Bleeding Due to Graft-vs-Host Disease. American Journal of Clinical Pathology, 2004, 122, 919-925.	0.7	22